AC
FATE icon

Aaron Cowen’s Fate Therapeutics FATE Stock Holding History

Aaron Cowen’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,562,852
Closed -$18.8M – 103
2024
Q1 		$18.8M Buy
+2,562,852
New +$15.9M 0.7% 41
2020
Q3 		– Sell
-75,000
Closed -$2.57M – 104
2020
Q2 		$2.57M Buy
+75,000
New +$2.24M 0.06% 68

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Aaron Cowen's FATE Position: Q2 2024 in Review

Aaron Cowen sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 2,562,852 shares — an estimated $18.8M sold.

Aaron Cowen first reported a position in FATE in Q2 2020 and held it in 2 quarters. The position peaked at $18.8M in Q1 2024. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Aaron Cowen reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Aaron Cowen sold 2,562,852 Fate Therapeutics shares in Q2 2024, an estimated $18.8M.
  • Aaron Cowen first reported a position in Fate Therapeutics in Q2 2020 and held it in 2 quarters.
  • Aaron Cowen's Fate Therapeutics position peaked at $18.8M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.